Eric Ostertag's guest appearances

Eric Ostertag

Finding Genius Podcast

Business Of Biotech

Drug Target Review Podcast

Hamid Khoja

James Thomas

Whitney Johnson

Alex Mashinsky

Ross Ulbricht

Lyn Ulbricht

Jameson Lopp

Marco Peereboom

Megan Ramos

Danny Flood

Abel James

Nir Eyal

Perry Marshall

Scott Young

Ben Goertzel

OwlTail

In this episode of Drug Target Review’s podcast, Deputy Editor Victoria Rees discusses cell and gene therapies with Dr Sam Wadsworth, Chief Scientific Officer of Ultragenyx Pharmaceutical and Dr Eric Ostertag, Chief Executive Officer of Poseida Therapeutics. Both will be presenting and speaking at the Cell &amp; Gene Therapy Advancements online summit on 3 – 4 November 2021 – find out more here: https://bit.ly/3Bo44joDr Wadsworth will be joining the session on combatting the immune response to AAV vectors and discussing the challenges associated with AAVs for gene therapy and why engineering better vectors could help to overcome these issues. In the podcast, he explores why AAV vectors are used to deliver gene therapy and the benefits they offer, as well as ways to reduce the dosage required. “AAV vectors are ideal for many applications and the basic simple reasons are that they have a great safety profile and they have a long duration of expression,” said Dr Wadsworth. “Today, we have clear proof that AAV vectors can be lifesaving… they have tremendous ability to deliver lifesaving therapies.”Dr Ostertag will join the session on utilising CAR T-cell therapies against solid tumours and will explore why CAR T-cell therapies are less effective in solid tumours than in blood cancers and how to minimise toxicity to ensure a targeted approach. In this episode, he covers why CAR T cells have shown success in haematological cancers and promising new developments that mean they could be used for a wide range of tumours. “Blood tumours are relatively easy to access for a CAR T product and that’s not always the case for solid tumour indications,” said Dr Ostertag. “There are other hypotheses that revolve around the so-called tumour microenvironment; meaning that solid tumours have certain characteristics – hypoxia in the centre of the tumour or checkpoint inhibitors that cause problems with the T cells killing the solid tumours – that can limit success.”Make sure you don’t miss out and reserve your spot at Drug Target Review’s Cell &amp; Gene Therapy Advancements online summit today: https://bit.ly/3Bo44jo

In this episode of Drug Target Review’s podcast, Deputy Editor Victoria Rees discusses cell and gene therapies with Dr Sam Wadsworth, Chief Scientific Officer of Ultragenyx Pharmaceutical and Dr Eric Ostertag, Chief Executive Officer of Poseida Therapeutics. Both will be presenting and speaking at the Cell &amp; Gene Therapy Advancements online summit on 3 – 4 November 2021 – find out more here: <a href="https://bit.ly/3Bo44jo" rel="nofollow" target="_blank">https://bit.ly/3Bo44jo</a> Dr Wadsworth will be joining the session on combatting the immune response to AAV vectors and discussing the challenges associated with AAVs for gene therapy and why engineering better vectors could help to overcome these issues. In the podcast, he explores why AAV vectors are used to deliver gene therapy and the benefits they offer, as well as ways to reduce the dosage required. “AAV vectors are ideal for many applications and the basic simple reasons are that they have a great safety profile and they have a long duration of expression,” said Dr Wadsworth. “Today, we have clear proof that AAV vectors can be lifesaving… they have tremendous ability to deliver lifesaving therapies.” Dr Ostertag will join the session on utilising CAR T-cell therapies against solid tumours and will explore why CAR T-cell therapies are less effective in solid tumours than in blood cancers and how to minimise toxicity to ensure a targeted approach. In this episode, he covers why CAR T cells have shown success in haematological cancers and promising new developments that mean they could be used for a wide range of tumours. “Blood tumours are relatively easy to access for a CAR T product and that’s not always the case for solid tumour indications,” said Dr Ostertag. “There are other hypotheses that revolve around the so-called tumour microenvironment; meaning that solid tumours have certain characteristics – hypoxia in the centre of the tumour or checkpoint inhibitors that cause problems with the T cells killing the solid tumours – that can limit success.” Make sure you don’t miss out and reserve your spot at Drug Target Review’s Cell &amp; Gene Therapy Advancements online summit today: <a href="https://bit.ly/3Bo44jo" rel="nofollow" target="_blank">https://bit.ly/3Bo44jo</a>

Episode 3 - Dr Sam Wadsworth, Ultragenyx Pharmaceutical & Dr Eric Ostertag, Poseida Therapeutics

Eric Ostertag, M.D., Ph.D., wanted to launch a biotech. When University of Pennsylvania department heads said no to a licensing deal for lack of a CEO, Dr. Ostertag convinced them he could run the company. Many bold moves later, Dr. Ostertag is founder and CEO at Poseida Therapeutics, a company that's doing things never seen before in the field of CAR T-cell and gene therapies for multiple myeloma and prostate cancer. On this week's episode of The Business of Biotech, Dr. Ostertag gives us a tour of the architecture supporting Poseida's unique 3-tiered development and manufacturing platform. Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

Eric Ostertag, M.D., Ph.D., wanted to launch a biotech. When University of Pennsylvania department heads said no to a licensing deal for lack of a CEO, Dr. Ostertag convinced them he could run the company. Many bold moves later, Dr. Ostertag is founder and CEO at Poseida Therapeutics, a company that's doing things never seen before in the field of CAR T-cell and gene therapies for multiple myeloma and prostate cancer. On this week's episode of The Business of Biotech, Dr. Ostertag gives us a tour of the architecture supporting Poseida's unique 3-tiered development and manufacturing platform. Subscribe to the NEW #BusinessofBiotech newsletter at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a> for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at <a href="https://www9.bioprocessonline.com/business-of-biotech-nl-sign-up/" rel="nofollow" target="_blank">bioprocessonline.com/bob</a>!

Building A DNA Delivery System With Poseida Tx CEO Eric Ostertag, M.D., Ph.D.

How can cancer be treated differently than how many others have accepted as standard? Gene therapy may be the solution to change the course of cancer treatment.  Listen in to learn:  The chances of getting cancer in your lifetime How CAR-T therapy operates How genetic therapies are limited  CEO of Poseida Therapeutics, Eric Ostertag, discusses his work to develop safe, single-treatment cures for cancer and other diseases. Since cancer has a genetic basis for operation,  gene therapy can be even more effective than the previously used viruses or other therapeutic techniques. Immuno-oncology is the bleeding edge of cancer treatment and has shown the most promising results in solid tumors. Due to the genetic limitations of viral technology, it does not have the capacity for efficacy found in non-viral therapeutics. The next generation of CAR-T will have higher chances of not being thwarted by mutations and solid tumors. Visit poseida.com for more information.  Episode also available on Apple Podcasts: apple.co/30PvU9C

How can cancer be treated differently than how many others have accepted as standard? Gene therapy may be the solution to change the course of cancer treatment. Listen in to learn: <ul> <li>The chances of getting cancer in your lifetime</li> <li>How CAR-T therapy operates</li> <li>How genetic therapies are limited</li> </ul> CEO of Poseida Therapeutics, Eric Ostertag, discusses his work to develop safe, single-treatment cures for cancer and other diseases. Since cancer has a genetic basis for operation, <a href="https://www.findinggeniuspodcast.com/podcasts/animal-genome-sequencing-and-crispr-cas9-gene-editing-steps-discussed-in-depth-with-alison-van-eenennaam/" rel="nofollow" target="_blank"> gene therapy</a> can be even more effective than the previously used viruses or other therapeutic techniques. Immuno-oncology is the bleeding edge of cancer treatment and has shown the most promising results in solid tumors. Due to the genetic limitations of viral technology, it does not have the capacity for efficacy found in non-viral therapeutics. The next generation of CAR-T will have higher chances of not being thwarted by mutations and solid tumors. Visit <a href="https://poseida.com" rel="nofollow" target="_blank">poseida.com</a> for more information. Episode also available on Apple Podcasts: <a href="https://podcasts.apple.com/us/podcast/id1169016854" rel="nofollow" target="_blank">apple.co/30PvU9C</a>

Using Gene Therapies to Fight Cancer and Tumor Cell Therapeutics - An In-Depth Discussion with Eric Ostertag